4-Isopropylcyclohexylisocyanat | 4796-18-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-Isopropylcyclohexylisocyanat
• 英文别名: 4-Isopropylcyclohexylisocyanate；1-isocyanato-4-propan-2-ylcyclohexane
• CAS: 4796-18-3
• 化学式: C₁₀H₁₇NO
• 分子量: 167.251
• InChiKey: LNUYKKUDFXIMPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Isopropylcyclohexylisocyanat 、 2,4,6-三甲氧基苯胺 在 吡啶 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 生成 N-(2,4,6-trimethoxyphenyl)-N'-(4-isopropylcyclohexyl)urea
  参考文献：
  名称：

  Cycloalkylurea compounds

  摘要：

  公式（I）的环烷基脲化合物：##STR1## 其中每个符号如规范中定义的那样，或其药学上可接受的盐，该化合物抑制ACAT并且可作为降血脂和抗动脉粥样硬化药物。

  公开号：

  US05420164A1

文献信息

• Cyclohexylurea compounds
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0507291A1

  公开（公告）日：1992-10-07

  A cycloalkylurea compound of the formula (I): wherein R¹ is a group of the formula (a): (wherein R⁶, R⁷ and R⁸ are the same or different and each is hydrogen or alkyl having 1 to 8 carbon atoms, with the proviso that compounds wherein two or three of R⁶, R⁷ and R⁸ are hydrogens are excluded), haloalkyl, cycloalkyl, alkoxy having 1 to 5 carbon atoms, phenyl, aralkyl or heteroaryl, or phenyl, aralkyl or heteroaryl each substituted on the aromatic ring by 1 to 3 substituents selected from alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 8 carbon atoms, cycloalkyl, cycloalkyloxy, haloalkyl, haloalkoxy, halogen, nitro, amino and substituted amino;    R² is hydrogen, phenyl or phenyl substituted by 1 to 3 substituents selected from alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, haloalkyl and halogen, whererin R¹ and R² may be substituted on the same carbon atom of cycloalkyl ring;    R¹ and R² together may form a substituted or unsubstituted cyclic hydrocarbon having 3 to 7 carbon atoms or a substituted or unsubstituted spiran;    R³ is hydrogen, alkyl having 1 to 8 carbon atoms, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylthioalkyl, aralkyl substituted by alkylenedioxy, aralkyl, aralkyloxyalkyl, aralkyl or aralkyloxyalkyl each substituted on the aromatic ring by 1 to 3 substituents selected from alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 5 carbon atoms, halogen, nitro, hydroxy, amino, substituted amino, haloalkyl, alkylthio, benzyloxy and benzylthio, heteroarylalkyl, phenoxyalkyl, or heteroarylalkyl or phenoxyalkyl each substituted on the aromatic ring by 1 to 3 substituents selected from halogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, nitro, amino and haloalkyl, or a group of the formula (c) or (d): wherein m is 1 or 2, R¹¹ is hydrogen or alkyl having 1 to 4 carbon atoms, R¹² is hydrogen, alkyl having 1 to 4 carbon atoms or aralkyl;    R⁴ is phenyl substituted by 1 to 3 substituents selected from alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, haloalkyl, halogen, amino and substituted amino;    n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof, which compound inhibits ACAT and is useful as hypolipidemic and anti-atherosclerotic medicine.

  式 (I) 的环烷基脲化合物： 其中 R¹ 是式 (a) 的基团： (其中 R⁶、R⁷ 和 R⁸ 相同或不同，且各自为氢或具有 1 至 8 个碳原子的烷基，但 R⁶、R⁷ 和 R⁸ 中的两个或三个为氢的化合物除外）、卤代烷基、环烷基、具有 1 至 5 个碳原子的烷氧基、苯基、芳基或杂芳基，或苯基、芳基或杂芳基、或在芳香环上被 1 至 3 个取代基取代的苯基、芳基或杂芳基，每个取代基均选自 1 至 4 个碳原子的烷基、1 至 8 个碳原子的烷氧基、环烷基、环烷氧基、卤代烷基、卤代烷氧基、卤素、硝基、氨基和取代氨基； R² 是氢、苯基或被 1 至 3 个取代基取代的苯基，这些取代基选自具有 1 至 4 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基、卤代烷基和卤素，其中 R¹ 和 R² 可在环烷基环的同一碳原子上被取代； R¹ 和 R² 可共同形成具有 3 至 7 个碳原子的取代或未取代的环烃或取代或未取代的螺烷； R³ 是氢、具有 1 至 8 个碳原子的烷基、环烷基、环烷基烷基、烷氧基烷基、烷硫基烷基、被亚烷基二氧基取代的芳基、芳烷基、芳氧基烷基、芳烷基或芳氧基烷基，每个芳环上被 1 至 3 个取代基取代，这些取代基选自具有 1 至 4 个碳原子的烷基、具有 1 至 5 个碳原子的烷氧基、卤素、硝基、羟基、氨基、取代的氨基、烷氧基烷基、烷硫基烷基、被亚烷基二氧基取代的芳烷基、芳氧基烷基、芳氧基烷基、芳氧基烷基或芳氧基烷基、羟基、氨基、取代氨基、卤代烷基、烷硫基、苄氧基和苄硫基、杂芳基烷基、苯氧基烷基、或芳环上各被 1 至 3 个取代基取代的杂芳基烷基或苯氧基烷基，这些取代基选自卤素、具有 1 至 4 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基、硝基、氨基和卤代烷基或式 (c) 或 (d) 的基团： 其中 m 为 1 或 2，R¹¹ 为氢或具有 1 至 4 个碳原子的烷基，R¹² 为氢、具有 1 至 4 个碳原子的烷基或芳烷基； R⁴ 是被 1 至 3 个取代基取代的苯基，这些取代基选自具有 1 至 4 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基、卤代烷基、卤素、氨基和取代氨基； n 为 1、2 或 3； 或其药学上可接受的盐、 该化合物可抑制 ACAT，可用作降血脂和抗动脉粥样硬化药物。
• DE1185180
  申请人：——

  公开号：——

  公开（公告）日：——
• 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia
  作者：Sampath-Kumar Anandan、Heather Kay Webb、Dawn Chen、Yi-Xin (Jim) Wang、Basker R. Aavula、Sylvaine Cases、Ying Cheng、Zung N. Do、Upasana Mehra、Vinh Tran、Jon Vincelette、Joanna Waszczuk、Kathy White、Kenneth R. Wong、Le-Ning Zhang、Paul D. Jones、Bruce D. Hammock、Dinesh V. Patel、Randall Whitcomb、D. Euan MacIntyre、James Sabry、Richard Gless

  DOI：10.1016/j.bmcl.2010.12.042

  日期：2011.2

  1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents. (C) 2010 Elsevier Ltd. All rights reserved.
• US5420164A
  申请人：——

  公开号：US5420164A

  公开（公告）日：1995-05-30
• Cycloalkylurea compounds
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05420164A1

  公开（公告）日：1995-05-30

  A cycloalkylurea compound of the formula (I): ##STR1## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, which compound inhibits ACAT and is useful as hypolipidemic and antiatherosclerotic medicine.

  公式（I）的环烷基脲化合物：##STR1## 其中每个符号如规范中定义的那样，或其药学上可接受的盐，该化合物抑制ACAT并且可作为降血脂和抗动脉粥样硬化药物。